Yuki Akazawa

1.0k total citations
40 papers, 546 citations indexed

About

Yuki Akazawa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Yuki Akazawa has authored 40 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 9 papers in Surgery. Recurrent topics in Yuki Akazawa's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Yuki Akazawa is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Yuki Akazawa collaborates with scholars based in Japan, United States and United Kingdom. Yuki Akazawa's co-authors include Tomokazu Hasegawa, Takamasa Kitamura, Asuna Sugimoto, Tsutomu Iwamoto, Aya Miyazaki, Satoshi Fukumoto, Keigo Yoshizaki, Masayuki Shono, Takeshi Uenami and Masaki Kanazu and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Yuki Akazawa

36 papers receiving 543 citations

Peers

Countries citing papers authored by Yuki Akazawa

Since Specialization

Citations

This map shows the geographic impact of Yuki Akazawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Akazawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Akazawa more than expected).

Fields of papers citing papers by Yuki Akazawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuki Akazawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Akazawa. The network helps show where Yuki Akazawa may publish in the future.

Co-authorship network of co-authors of Yuki Akazawa

This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Akazawa. A scholar is included among the top collaborators of Yuki Akazawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Akazawa. Yuki Akazawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Iroquois homeobox 3 regulates odontoblast proliferation and differentiation mediated by Wnt5a expression 2023 ·Biochemical and Biophysical Research Communications ·(unknown), Aya Miyazaki, (unknown), (unknown), Asuna Sugimoto, Yasusei Kudo, (unknown), (unknown), Yuki Akazawa, Takamasa Kitamura, Hiroshi Nakagawa, (unknown), Tomokazu Hasegawa, Keigo Yoshizaki, Satoshi Fukumoto, Akihito Yamamoto, Naozumi Ishimaru, Tomonori Iwasaki, Tsutomu Iwamoto	2
2	The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer 2023 ·Oncology ·Satoshi Igawa, Hiroki Yamamoto, (unknown), Yuki Akazawa, (unknown), (unknown), Yoshiro Nakahara, Takashi Sato, Hisashi Mitsufuji, Jiichiro Sasaki, Katsuhiko Naoki	3
3	The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors 2023 ·Oncology ·Yuki Akazawa, Satoshi Igawa, (unknown), (unknown), (unknown), (unknown), (unknown), Masashi Kasajima, Yoshiro Nakahara, Takashi Sato, Hisashi Mitsufuji, (unknown), Masaru Kubota, Jiichiro Sasaki, Katsuhiko Naoki	4
4	The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer 2022 ·Oncology ·Masashi Kasajima, Satoshi Igawa, (unknown), (unknown), Yuki Akazawa, Hideaki Manabe, (unknown), Hiroki Yamamoto, Hiroki Ito, (unknown), Yoshiro Nakahara, Takashi Sato, (unknown), Masanori Yokoba, Masaru Kubota, Jiichiro Sasaki, Katsuhiko Naoki	6
5	Coordination of WNT signaling and ciliogenesis during odontogenesis by piezo type mechanosensitive ion channel component 1 2019 ·Scientific Reports ·Aya Miyazaki, Asuna Sugimoto, Keigo Yoshizaki, (unknown), (unknown), (unknown), Takamasa Kitamura, Kunihiro Otsuka, Tomokazu Hasegawa, Yuki Akazawa, Satoshi Fukumoto, Naozumi Ishimaru, Tsutomu Iwamoto	50
6	Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report 2019 ·Thoracic Cancer ·Ryuya Edahiro, Mikako Ishijima, (unknown), Kohei Nishida, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Masahide Mori	12
7	Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316) 2018 ·BMC Cancer ·Motoko Tachihara, Shunichi Negoro, Takako Inoue, Motohiro Tamiya, Yuki Akazawa, Takeshi Uenami, Yoshiko Urata, Yoshihiro Hattori, Akito Hata, Nobuyuki Katakami, Soichiro Yokota	32
8	Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study 2018 ·PLoS ONE ·Yukihiro Yano, (unknown), Ryuya Edahiro, Yuki Hosono, (unknown), Kohei Nishida, (unknown), Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori	6
9	Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression 2018 ·Annals of Translational Medicine ·Takeshi Uenami, Mikako Ishijima, Masaki Kanazu, (unknown), Ryuya Edahiro, Kohei Nishida, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori	3
10	Piezo type mechanosensitive ion channel component 1 functions as a regulator of the cell fate determination of mesenchymal stem cells 2017 ·Scientific Reports ·Asuna Sugimoto, Aya Miyazaki, (unknown), Masayuki Shono, Yuki Akazawa, Tomokazu Hasegawa, (unknown), Takamasa Kitamura, Keigo Yoshizaki, Satoshi Fukumoto, Tsutomu Iwamoto	199
11	Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report 2017 ·Lung Cancer ·Takeshi Uenami, Yuki Hosono, Mikako Ishijima, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Masahide Mori, Toshihiko Yamaguchi, Soichiro Yokota	36
12	Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection 2017 ·Molecular and Clinical Oncology ·Yuki Akazawa, Masahiko Higashiyama, Kazumi Nishino, (unknown), Toru Kumagai, Takako Inoue, Ayako Fujiwara, Toshiteru Tokunaga, Jiro Okami, Fumio Imamura, Ken Kodama, Hisayuki Kobayashi	1
13	Recruitment of mesenchymal stem cells by stromal cell-derived factor 1α in pulp cells from deciduous teeth 2015 ·International Journal of Molecular Medicine ·Yuki Akazawa, Tomokazu Hasegawa, Yoshitaka Yoshimura, Naoyuki Chosa, (unknown), (unknown), Asuna Sugimoto, Takamasa Kitamura, Hiroshi Nakagawa, Akira Ishisaki, Tsutomu Iwamoto	15
14	Dental findings and management in a child with hypomelanosis of Ito 2014 ·Pediatric Dental Journal ·Tomokazu Hasegawa, Yuki Akazawa, Takamasa Kitamura, Asuna Sugimoto, (unknown), Tsutomu Iwamoto	0
15	The role of extracellular ATP-mediated purinergic signaling in bone, cartilage, and tooth tissue 2014 ·Journal of Oral Biosciences ·Tsutomu Iwamoto, Asuna Sugimoto, Takamasa Kitamura, Yuki Akazawa, Tomokazu Hasegawa	4
16	Analysis of Circulating Tumor EGFR-DNA in Plasma During EGFR-TKI Therapy of EGFR Mutation-Positive Lung Cancer Patients 2013 ·Annals of Oncology ·Junji Uchida, (unknown), Takako Okuyama, Kazumi Nishino, Toru Kumagai, Yuki Akazawa, Fumio Imamura	1
17	Forced mastication increases survival of adult neural stem cells in the hippocampal dentate gyrus 2012 ·International Journal of Molecular Medicine ·Yuki Akazawa, Takamasa Kitamura, (unknown), Yoshitaka Yoshimura, Masato Mitome, Tomokazu Hasegawa	17
18	A Retrospective Study of the Novel Combination of Paclitaxel and S1 for Pretreated Advanced Non-Small Cell Lung Cancer 2012 ·Chemotherapy ·(unknown), Yuri Ito, Kazumi Nishino, Junji Uchida, Toru Kumagai, Yuki Akazawa, Takako Okuyama, Tetsuhiro Yoshinami, Fumio Imamura	4
19	Epstein–Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma 2011 ·International Journal of Hematology ·Toshinari Yagi, Jun Ishikawa, (unknown), Yukiko Yamashita, (unknown), Tetsuhiro Yoshinami, Yuki Akazawa, Daisuke Sakai, Sachiko Yamamoto, (unknown), (unknown), Naotoshi Sugimoto, Hitoshi Yoshida, Yasuhiko Tomita, Fumio Imamura	3
20	Endotracheal Bronchogenic Cyst 2011 ·Journal of Bronchology & Interventional Pulmonology ·Takako Okuyama, Yuki Akazawa, Junji Uchida, Kazumi Nishino, Toru Kumagai, Fumio Imamura	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact